このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

AI によるプラーク定量化: 効果的な CAD 管理を決定するための CCTA および AI-QCPA (DECIDE)

2026年11月17日 更新者:HeartFlow, Inc.

DECIDE レジストリ: AI 由来のプラーク定量化: 効果的な CAD 管理を決定するための CCTA および AI-QCPA

The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).

調査の概要

状態

積極的、募集していない

詳細な説明

The DECIDE Registry is a post-market, multi-center, data collection study assessing the change in management of clinically stable patients who undergo CCTA with plaque detected. Data will be retrospectively collected following the CCTA, and analyses will be completed 90 days, 180 days, and 1 year after CCTA. Data may be retrospectively collected annually up to 5 years.

研究の種類

観察的

入学 (推定)

20000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • North Carolina
      • Greensboro、North Carolina、アメリカ、27401
        • Moses Cone Memorial Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Deidentified data will be collected for all patients who have had a CCTA with plaque detected or a stress test and are included by the site in the registry.

説明

Inclusion Criteria (all must be present) :

  1. Groups 1, 2,4,5 and 6: CCTA and plaque detected
  2. Group 3: Any patient with a stress test (stress echocardiogram or nuclear imaging including SPECT or PET) and no CCTA within the 90 days prior to site activation
  3. Groups 1,2,3 and 4: Clinically stable, symptomatic
  4. Group 6: Clinically stable without symptoms suggestive of CAD at the time of the CCTA

Exclusion Criteria (all must be absent) :

  1. ED presentation (at the time of the CCTA or stress test)
  2. Groups 1,2,3,4, and 6: Previous history of CAD (prior to the CCTA or stress test with history of revascularization)
  3. Group 5: Prior history of PCI in multiple vessel territories, PCI in the Left Main, CABG, and/or any other conditions or limitations which would prevent successful CCTA processing by HeartFlow
  4. Acute chest pain (in patients who have not been ruled out for ACS)
  5. Previously evaluated with and/or in a study which includes AI-QCPA

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
介入・治療
Group 1: No AI-QCPA

This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. No AI-QCPA will be provided.

Group 2: Delayed AI-QCPA

This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. Ninety days following the CCTA, an AI-QCPA report will be provided to the CCTA reader who will in turn provide it to the treating clinician. The treating clinician will decide if changes to medical management are required to effectively treat the patient and if so, treating clinician will contact the patient with the new treatment plan.

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Group 3: Stress Test Only

This group includes symptomatic patients who previously had non-invasive stress testing only with no CCTA and no prior revascularization. No AI-QCPA will be provided.

Group 4: Prospective AI-QCPA, symptomatic without prior revascularization

This group includes newly scanned, symptomatic patients with plaque detected and no prior revascularization. Patients in this group will have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Group 5: Prospective AI-QCPA, prior PCI

This group includes newly scanned patients with plaque detected. Patients in this group can by symptomatic or asymptomatic and will have had prior PCI in only one vessel territory (CABG patients are not eligible). CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Group 6: Prospective AI-QCPA, asymptomatic without prior revascularization

This group includes newly scanned, asymptomatic patients with plaque detected and no prior revascularization. Patients in this group will not have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Primary Endpoint
時間枠:90 Days

The primary endpoint of the DECIDE Registry is the change in medical management following HeartFlow AI-QCPA at 90 days compared to medical management following CCTA alone. The primary endpoint will only be assessed in patients in Group 2.

90 Days

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in LDL levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Change in HbA1c levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Changes in Non HDL levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Changes in HDL levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Changes in TG levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Changes in weight
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Reclassification rate of medical management (across the groups)
時間枠:90 Days, 180 Days and 365 Days

Change in preventive medical management (lower or intensify).

90 Days, 180 Days and 365 Days
Rates of referral to invasive coronary angiography and coronary revascularization (PCI+CABG)
時間枠:90 Days, 180 Days and 365 Days

across the groups

90 Days, 180 Days and 365 Days
Reclassification rate of symptoms
時間枠:90 Days, 180 Days and 365 Days

Improvement in symptoms across the groups

90 Days, 180 Days and 365 Days
Number of CV hospitalizations
時間枠:At 365 Days (and potentially out to 5 years)

across the groups

At 365 Days (and potentially out to 5 years)
Number of Revascularizations
時間枠:365 Days

At one year across the groups

365 Days

その他の成果指標

結果測定
メジャーの説明
時間枠
Number of MACE (CV-related death, MI, or CAD hospitalization)
時間枠:At 365 Days (and potentially out to 5 years)

Exploratory & safety endpoints will be compared across the groups unless otherwise noted

At 365 Days (and potentially out to 5 years)
Timing of referral to other provider(s) for management
時間枠:Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA

across the groups unless otherwise noted

Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
Timing of lab orders (Group 1 vs. Group 2)
時間枠:Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA

across the groups unless otherwise noted

Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
Change in Lp(a) (Group 2)
時間枠:Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups unless otherwise noted

Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Change in Lp(a) (Group 4 compared to Group 1)
時間枠:Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups unless otherwise noted

Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Rate of cardiac testing
時間枠:At 365 Days (and potentially out to 5 years)

Efficiency of testing based upon imaging and reports for all other cardiac tests including CCTA, SPECT, echo, CAC, and stress echo

At 365 Days (and potentially out to 5 years)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Sarah Rinehart, MD、CAMC Health System
  • 主任研究者:Leslee Shaw, MD、MOUNT SINAI HOSPITAL

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年3月27日

一次修了 (実際)

2026年3月27日

研究の完了 (推定)

2030年3月27日

試験登録日

最初に提出

2024年3月28日

QC基準を満たした最初の提出物

2024年4月17日

最初の投稿 (実際)

2024年4月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月17日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • CP-910-001

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する